The purpose is to determine if the NeuRx(R) Diaphragm Pacing SystemTM (DPS) for people with ALS and hypoventilation is associated with improved survival or diaphragm function. Subjects will be randomly assigned in a 2:1 ratio to DPSX or standard of care (control) treatment. The DPS group will have the DPS device surgically implanted. Subjects will remain on DPS or standard of care treatment for the duration of the study (12-36 months).
Who may be Eligible
21 years of age or older; be diagnosed with familial or sporadic ALS; have hypoventilation